De Nunzio Cosimo, Trucchi Alberto, Miano Roberto, Stoppacciaro Antonella, Fattahi Hassan, Cicione Antonio, Tubaro Andrea
Departments of Urology and Pathology (AS), Sant'Andrea Hospital, University La Sapienza, Rome, Italy.
J Urol. 2009 Mar;181(3):1069-74; discussion 1074-5. doi: 10.1016/j.juro.2008.10.163. Epub 2009 Jan 16.
We evaluated the association between the number of biopsy cores revealing high grade prostatic intraepithelial neoplasia and prostate cancer in an era of extended biopsy protocol.
From December 2004 to September 2007 patients referred to our clinic with a prostate specific antigen of 4 ng/ml or greater or an abnormal digital rectal examination were scheduled for transrectal ultrasound prostatic biopsy with a 12-core template. In patients with high grade prostatic intraepithelial neoplasia we proposed a second prostate specific antigen evaluation and a new 12-core biopsy after 6 months independent of prostate specific antigen. Nonparametric tests were applied for statistical analysis.
We evaluated 650 patients. Of the 147 patients (22%) with high grade prostatic intraepithelial neoplasia 117 underwent a second biopsy 6 months later. Patient characteristics (age, prostate specific antigen, free-to-total prostate specific antigen ratio, prostate volume, prostate specific antigen density) were similar at initial and repeat biopsy. On second biopsy 22 patients (18.8%) presented with prostate cancer (14 with Gleason score 6, 7 with Gleason score 7 and 1 with a Gleason score 8), 75 showed isolated high grade prostatic intraepithelial neoplasia (64.2%) and 20 (17%) had chronic prostatitis. The number of cores (4 or more) involved with high grade prostatic intraepithelial neoplasia on the first biopsy was significantly associated with prostate cancer on the second biopsy (p = 0.001). Prostate specific antigen could not be used to distinguish prostate cancer from benign disease or high grade prostatic intraepithelial neoplasia.
The number of cores with high grade prostatic intraepithelial neoplasia seems to be associated with the presence of cancer on second biopsy. A 6-month biopsy is recommended in patients with high grade prostatic intraepithelial neoplasia when 4 or more cores with high grade prostatic intraepithelial neoplasia are detected in the initial biopsy sample independent of prostate specific antigen.
我们评估了在延长活检方案时代,显示高级别前列腺上皮内瘤变的活检芯数量与前列腺癌之间的关联。
2004年12月至2007年9月,将前列腺特异性抗原为4 ng/ml或更高或直肠指检异常的患者转诊至我们诊所,安排采用12芯模板进行经直肠超声引导下前列腺活检。对于高级别前列腺上皮内瘤变患者,我们建议在6个月后进行第二次前列腺特异性抗原评估和新的12芯活检,且不考虑前列腺特异性抗原水平。采用非参数检验进行统计分析。
我们评估了650例患者。147例(22%)高级别前列腺上皮内瘤变患者中,117例在6个月后进行了第二次活检。初次活检和重复活检时患者特征(年龄、前列腺特异性抗原、游离前列腺特异性抗原与总前列腺特异性抗原比值、前列腺体积、前列腺特异性抗原密度)相似。第二次活检时,22例患者(18.8%)患有前列腺癌(14例Gleason评分为6分,7例Gleason评分为7分,1例Gleason评分为8分),75例显示孤立性高级别前列腺上皮内瘤变(64.2%),20例(17%)患有慢性前列腺炎。初次活检时涉及高级别前列腺上皮内瘤变的芯数量(4个或更多)与第二次活检时的前列腺癌显著相关(p = 0.001)。前列腺特异性抗原不能用于区分前列腺癌与良性疾病或高级别前列腺上皮内瘤变。
显示高级别前列腺上皮内瘤变的活检芯数量似乎与第二次活检时癌症的存在有关。当初次活检样本中检测到4个或更多显示高级别前列腺上皮内瘤变的芯时,无论前列腺特异性抗原水平如何,建议对高级别前列腺上皮内瘤变患者在6个月后进行活检。